Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice

2024-9-18

Imaging in vasculitis

2024-9-12

The role of neutrophil extracellular traps in inflammatory rheumatic diseases

2024-9-11

Gastrointestinal disease in systemic sclerosis: the neglected organ system?

2024-8-29

Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results

2024-8-28

Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research

2024-8-26

Clinical endpoints in myositis: challenges and ways forward

2024-8-23

Cross-tissue organization of myeloid cells in scleroderma and related fibrotic diseases

2024-8-23

Current approach to muscle imaging in myositis

2024-8-23

Autoantibody testing in myositis: an update

2024-8-20

From traditional to targeted: the changing trajectory of therapies in dermatomyositis

2024-8-14

Interstitial lung disease and myositis

2024-8-13

Current efforts and historical perspectives on classification of idiopathic inflammatory myopathies

2024-8-13

Heart involvement in systemic sclerosis: emerging concepts

2024-8-9

Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI

2024-8-8

Editorial introduction

2024-8-1

Calcinosis in dermatomyositis

2024-7-25

Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis

2024-7-24

Antimelanoma differentiation antigen 5-positive dermatomyositis: an update

2024-7-15

SGLT-2 inhibitors: new horizons for rheumatologists

2024-7-15

Update on antineutrophil cytoplasmic autoantibody vasculitis in children

2024-7-11

Current management of giant cell arteritis and its complications

2024-6-26

Editorial introduction

2024-5-30

Novel therapies in juvenile idiopathic arthritis

2024-5-23

Renal disease in pediatric rheumatology

2024-5-16

Updates in the care and management of children and adolescents with systemic lupus erythematosus

2024-5-16

Disease modification in axial spondyloarthritis – still a controversy?

2024-5-7

Investigating gout flares: beyond a definition

2024-5-2

Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis

2024-5-1

Sacroiliitis in inflammatory bowel disease

2024-4-30

Axial spondyloarthritis guidelines – aiming for maximum impact

2024-4-25

50 years of spondyloarthritis: a look back and a look ahead

2024-4-24

An update on topical therapies for psoriasis

2024-4-23

Drug therapy in juvenile spondyloarthritis

2024-4-19

Artificial intelligence and machine learning in axial spondyloarthritis

2024-3-27

Editorial introductions

2024-3-26

Chimeric antigen receptors: “CARs” in the fast lane for rheumatology

2024-3-26

Rheumatoid arthritis – the challenge of heterogeneity

2024-3-22

Safety of biologic agents for the management of rheumatic diseases during pregnancy

2024-3-11

Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention

2024-3-5

Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities

2024-2-29

Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond

2024-2-26

Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis

2024-2-23

Management of postinfectious inflammatory arthritis

2024-2-21

Cardiovascular complications of rheumatoid arthritis

2024-2-9

Emerging biologic therapies for systemic lupus erythematosus

2024-2-1

Editorial introductions

2024-2-1

Describing calcium pyrophosphate deposition: undoing the tower of Babel!

2024-1-31

Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?

2024-1-31

New molecular targets in the treatment of rheumatoid arthritis

2024-1-2